Jasper Therapeutics Q3 loss smaller than estimates

Reuters

11/10

<a href="https://laohu8.com/S/JSPR">Jasper Therapeutics</a> Q3 loss smaller than estimates

Overview

Jasper Q3 loss per share beats analyst expectations despite net loss of $18.7 mln
Company completed $30 mln stock offering, extending cash runway through H1 2026

Outlook

Company plans to report final conclusions from investigation into BEACON study anomalies in Q4 2025
Company expects initial data from ETESIAN study in allergic asthma in Q4 2025
Jasper aims to complete dose selection for Phase 2b CSU study by mid-2026

Result Drivers

FINANCIAL POSITION - $30 mln stock offering completed, extending cash runway through H1 2026

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS	Beat	-$1.13	-$1.21 (7 Analysts)
Q3 Net Income		-$18.70 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Jasper Therapeutics Inc is $10.50, about 83% above its November 7 closing price of $1.78

Press Release: ID:nGNXyRBV4

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582790878"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582790878\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582790878?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582790878","market":"nz","top_or_hot":-1,"title":"Jasper Therapeutics Q3 loss smaller than estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/JSPR\">Jasper Therapeutics</a> Q3 loss smaller than estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Jasper Q3 loss per share beats analyst expectations despite net loss of $18.7 mln</p></li><li><p>Company completed $30 mln stock offering, extending cash runway through H1 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans to report final conclusions from investigation into BEACON study anomalies  in Q4 2025</p></li><li><p>Company expects initial data from ETESIAN study in allergic asthma in Q4 2025</p></li><li><p>Jasper aims to complete dose selection for Phase 2b CSU study by mid-2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FINANCIAL POSITION - $30 mln stock offering completed, extending cash runway through H1 2026</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Beat</p></td><td><p>-$1.13</p></td><td><p>-$1.21 (7 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$18.70 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Jasper <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $10.50, about 83% above its November 7 closing price of $1.78</p></li></ul><p>Press Release: <span>ID:nGNXyRBV4</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jasper Therapeutics Q3 loss smaller than estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJasper Therapeutics Q3 loss smaller than estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 21:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/JSPR\">Jasper Therapeutics</a> Q3 loss smaller than estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Jasper Q3 loss per share beats analyst expectations despite net loss of $18.7 mln</p></li><li><p>Company completed $30 mln stock offering, extending cash runway through H1 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans to report final conclusions from investigation into BEACON study anomalies  in Q4 2025</p></li><li><p>Company expects initial data from ETESIAN study in allergic asthma in Q4 2025</p></li><li><p>Jasper aims to complete dose selection for Phase 2b CSU study by mid-2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FINANCIAL POSITION - $30 mln stock offering completed, extending cash runway through H1 2026</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Beat</p></td><td><p>-$1.13</p></td><td><p>-$1.21 (7 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$18.70 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Jasper <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $10.50, about 83% above its November 7 closing price of $1.78</p></li></ul><p>Press Release: <span>ID:nGNXyRBV4</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0HG:1","article_id":"2582790878","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582790878","pubTimestamp":1762780105,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jasper Therapeutics Q3 loss smaller than estimatesOverviewJasper Q3 loss per share beats analyst expectations despite net loss of $18.7 mlnCompany completed $30 mln stock offering, extending cash runw","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","JSPR":"Jasper Therapeutics"},"translate_title":"Jasper Therapeutics第三季度亏损小于预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JSPR":0.9},"content_text":"Jasper Therapeutics Q3 loss smaller than estimatesOverviewJasper Q3 loss per share beats analyst expectations despite net loss of $18.7 mlnCompany completed $30 mln stock offering, extending cash runway through H1 2026OutlookCompany plans to report final conclusions from investigation into BEACON study anomalies  in Q4 2025Company expects initial data from ETESIAN study in allergic asthma in Q4 2025Jasper aims to complete dose selection for Phase 2b CSU study by mid-2026Result DriversFINANCIAL POSITION - $30 mln stock offering completed, extending cash runway through H1 2026Key DetailsMetricBeat/MissActualConsensus EstimateQ3 EPSBeat-$1.13-$1.21 (7 Analysts)Q3 Net Income-$18.70 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Jasper Therapeutics Inc is $10.50, about 83% above its November 7 closing price of $1.78Press Release: ID:nGNXyRBV4For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}